Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 178,140,960
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.81
  • Price/Sales 4.51
  • Price/Cash Flow 11.32
  • Price/Book 4.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.15 +4.79%
on 08/23/17
66.41 -1.93%
on 09/18/17
+2.71 (+4.34%)
since 08/22/17
3-Month
61.16 +6.49%
on 08/18/17
66.41 -1.93%
on 09/18/17
-0.89 (-1.35%)
since 06/22/17
52-Week
58.29 +11.73%
on 11/03/16
66.80 -2.50%
on 03/01/17
+2.11 (+3.35%)
since 09/22/16

Most Recent Stories

More News
FDA Approves Merck's KEYTRUDA(R) (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA(R) (pembrolizumab), the company's...

MRK : 65.13 (-0.72%)
Gilead's (GILD) Epclusa Receives Label Expansion in Canada

Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

MRK : 65.13 (-0.72%)
ABBV : 87.48 (+0.08%)
GILD : 83.27 (+0.79%)
KITE : 179.30 (-0.04%)
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
KITE : 179.30 (-0.04%)
PFE : 35.96 (-0.03%)
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com

The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.

AAPL : 151.89 (-0.98%)
JPM : 94.83 (-0.21%)
JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
PG : 92.24 (-0.43%)
FB : 170.54 (-0.33%)
PFE : 35.96 (-0.03%)
BA : 256.45 (+0.16%)
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune Pharma, Eli Lilly, and Merck

If you want a Stock Review on ALQA, IMNP, LLY, or MRK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 22, 2017, US markets...

IMNP : 1.15 (+2.68%)
ALQA : 0.42 (unch)
MRK : 65.13 (-0.72%)
LLY : 83.91 (+0.70%)
Merck Opens China's First BioReliance® End-to-End Biodevelopment Center in Shanghai

- Company's first end-to-end center outside of Europe

MRK : 65.13 (-0.72%)
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA(®) (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell lung...

MRK : 65.13 (-0.72%)
Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

CELG : 143.89 (+0.08%)
MRK : 65.13 (-0.72%)
ABBV : 87.48 (+0.08%)
RHHBY : 32.0200 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 65.93
1st Resistance Point 65.53
Last Price 65.13
1st Support Level 64.90
2nd Support Level 64.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.